evaluating the association between NSAIDs and breast cancer that were published between 1980 and 2000. One study (Rosenberg et al, 1991) was excluded from the analysis because of lack of data on the estimator of relative risk. The remaining studies were 6 cohort studies (Table 1 ) and 8 case-control studies ( Table 2 ). The number of cases ranged from 14 to 2414 for cohort studies. For case-control studies the number of cases ranged from 252 to 5882 and the number of controls ranged from 42 to 89528. 5 studies (Paganini-Hill et al, 1989; Thun et al, 1993; Schreinemachers and Emerson, 1994; Egan et al, 1996; Neugut et al, 1998) were restricted to aspirin use and three studies (Harris et al, 1999; Paganini-Hill et al, 1989; Friedman and Ury, 1980) provided data stratified by NSAID type.
Twelve studies reported reduction in the risk of breast cancer with NSAID use. The estimator of relative risk for cohort studies ranged from 0.20 to 1.01 and 6 of these estimators were significant. Only one cohort study (Egan et al, 1996) reported nonsignificant increases in the risk of breast cancer with aspirin use. The estimator of relative risk for case-control studies ranged from 0.57 to 1.00 and 7 of these estimators were significant. None of the case-control studies reported an increase in the risk of breast cancer with any NSAID use.
The results of meta-analyses are presented in Table 3 . Significant heterogeneity was detected among the studies (χ 2 = 53.0, P = 0.001). The combined estimate of relative risk using the random-effect model was 0.82 (95% CI = 0.75-0.89). Heterogeneity among studies was significantly reduced when studies were combined within specific design and type of control. The combined estimate of relative risk for cohort studies was 0.78 (95% CI 0.62-0.99) with any NSAIDs and was 0.79 (95% Six studies provided results on duration of use of aspirin and that of other NSAIDs (Table 4) . 9 studies provided results stratified by measures of NSAID use (Table 4 ). The risk reduction for highest duration of use (20+ years) ranged from 40% (Coogan et al, 1999) to zero (Egan et al, 1996) . Trend tests for dose-response relations in only one of these studies was significant. The available data in Table 4 are insufficient to estimate the combined dose-response effect for duration of use of any particular types of NSAID.
Seven studies provided results on frequency of use of aspirin and that of other NSAID (Table 5 ). In one study (Harris et al, 1999) four or more pills of NSAID per week was associated with a 43% reduction in the risk of breast cancer (RR = 0.57, 95% CI 0.44-0.74). In another study (Paganini-Hill et al, 1989 ) daily use of aspirin was associated with only 4% reduction in the estimated risk of breast cancer (RR = 0.96, 95% CI 0.69-1.34). The available data in Table 5 are insufficient to estimate the combined dose-response effect for frequency of use of any particular types of NSAID.
There was no evidence of publication bias in studies included in this meta-analysis. The Kendall tau correlation coefficient for the standard error and the standardized log odds ratio was 0.96 (P = 0.34).
DISCUSSION
This meta-analysis showed that NSAID use may decrease the risk of breast cancer. This is evident by the consistently reduced relative risk in the majority of studies included in the analysis. The effect observed was similar in most studies regardless of design or type of cases (incident or fatal cases). The only negative study (Egan et al, 1996) may have been confounded by reproductive factors. In this meta-analysis, regular use of NSAIDs was associated with an 18% reduction in the risk of breast cancer. The reduction in risk was higher in cohort studies (21%) than case-control studies (13%). Within case-control studies, the reduction in risk was smaller in studies with cancer controls than in those with non-cancer controls. Although this finding is consistent with studies on NSAID use and colon cancer (Harris et al, 1995) , it may argue against a true effect against breast cancer since this should be consistent across control groups. It is possible that some cancer subtypes (for example, gastrointestinal) were related to NSAID use and these patients discontinued the drug. If so this may overestimate the odds ratio and may bias the estimate of relative risk away from the null value. It is possible that the results of these studies are biased by a higher prevalence of preexisting medical conditions commonly associated with NSAID use among non-cancer controls. On the other hand population-based case-control studies (Neugut et al, 1998) used as control subjects who underwent screening mammography, and their use of NSAID could have overestimated the prevalence of use in the study base.
With regard to type of NSAID, aspirin was the major type used in the studies included in this meta-analysis. In general, the reduction in risk of breast cancer with aspirin use was similar to other NSAID type. Two studies reported higher reduction in risk with ibuprofen in comparison to aspirin. However, available data were not adequate enough to test this in a meta-analysis.
Nine studies evaluated dose-response relation of NSAID use and breast cancer but only two studies reported significant doseresponse relation for duration (Coogan et al, 1999) and frequency (Sharpe et al, 2000) of NSAID use. In one study (Coogan et al, 1999 ) the highest reduction in breast cancer risk was reported for the category 'unknown years of use'.
Although publication bias is possible because of the possibility of failure of investigators to submit negative results or failure of journals to publish negative studies our analysis did not suggest this.
The effect of NSAIDs on breast cancer risk reduction is biologically plausible. A number of animal studies have suggested a protective effect of NSAIDs against mammary cancer. A potential mechanism for anti-tumour effect of NSAIDs involves inhibition of the synthesis of prostaglandins. NSAIDs block the enzyme cyclooxygenase and in turn inhibit prostaglandin biosynthesis. Prostaglandins may serve as cofactors in carcinogenesis with potential effects ranging from direct mutagenesis to tumour promotion and immune suppression (Lupulescu, 1978; Mellemkjaer et al, 1996) . One study (McCormick and Wilson, 1986) suggests that the cancer inhibitory effects of NSAIDs may be independent of their effects on prostaglandin synthesis. There is evidence from animal studies that indomethacin inhibits the effects of oestrogen in the pituitary gland (Neugut et al, 1998) . Invitro studies of human breast cancer cells indicate that acetylsalicylic acid may inhibit direct binding of oestradiol to oestrogen receptor (Thompson et al, 1995) .
The majority of studies included in this meta-analysis adjusted for known risk factor for breast cancer. Our inclusion of estimators of relative risk, which were adjusted for the greatest number of confounders, would have reduced the possibility of confounding effect. The combined estimate of this study supports a protective effect for NSAIDs against breast cancer. Other support for the protective effect of NSAIDs against breast cancer comes from studies on patients with rheumatoid arthritis who use NSAIDs in high doses for symptom relief. 2 studies (Gridley et al, 1993; Baron, 1995) reported that these patients had less than expected occurrence of breast cancer. The risk pattern for NSAID users found in this meta-analysis is consistent with the pattern found in studies on patients with rheumatoid arthritis.
The limitations of this study stem from the studies included in the meta-analysis. All the studies included are observational studies and therefore subject to biases. Some are case-control studies and we cannot rule out the possibility of selection and information biases. It is possible that the relation between NSAIDs and breast cancer may reflect a recall bias by the cases or controls. Misclassification of exposure is a potential problem in observational epidemiological studies. None of the studies included in this meta-analysis utilized an objective method of exposure assessment. In all studies the NSAID use was self-reported and therefore subject to recall bias. These drugs are often taken sporadically in a pattern of intake that may be difficult to remember or summarize for some subjects. For example, some widely used brands or combination product may not be recognized as containing aspirin (Harris et al, 1995) . It is possible that NSAID use may reflect a health consciousness among the control group. However, Harris et al (1995) reported no association between NSAID use and level of education, which can be taken as a proxy for health consciousness.
Currently known risk factors account for less than half of all breast cancer cases and offer limited opportunities for intervention. Therefore, any preventive measure identified will be important. This meta-analysis suggests that NSAIDs have a weak chemopreventive value against breast cancer. However, we cannot rule out the possibility of an alternate explanation for this finding due to the limitations of the studies included in the analysis.
There is a need for more studies that prospectively evaluate the reduction in risk of breast cancer utilizing a better measure of NSAID dose. There is a need to establish whether NSAIDs are
